» Articles » PMID: 21334406

Epithelial Mesenchymal Transition and Hedgehog Signaling Activation Are Associated with Chemoresistance and Invasion of Hepatoma Subpopulations

Overview
Journal J Hepatol
Publisher Elsevier
Specialty Gastroenterology
Date 2011 Feb 22
PMID 21334406
Citations 104
Authors
Affiliations
Soon will be listed here.
Abstract

Background & Aims: Our previous studies showed that CD133, EpCAM, and aldehyde dehydrogenase (ALDH) are useful markers to identify cancer stem cells (CSCs) in hepatocellular carcinoma (HCC) tissues. The present study aims to evaluate chemosensitivity and invasion capability of HCC based on CSC marker profiles, and to explore the underlying molecular mechanisms.

Methods: Hepatoma cell lines were separated into subpopulations according to CD133, EpCAM, and ALDH expression profiles. Epithelial mesenchymal transition (EMT) and hedgehog (Hh) signaling were examined to identify their links with chemoresistance and aggressive invasion.

Results: Well-differentiated cell lines were positive for CD133(+)/ALDH(high) and CD133(+)/EpCAM(+) at 1.5-15% and 2.3-8.3%; whereas, poorly-differentiated cells were almost all negative for these markers. FACS-enriched CD133(+)/ALDH(high) and CD133(+)/EpCAM(+) Hep3B and Huh-7 cells formed more spheroids in vitro. CD133(-)/ALDH(low) HLE cells were more resistant to cisplatin, doxorubicin or sorafenib than their positive counterparts. CD133(-)/EpCAM(-) Huh-7 cells or CD133(-)/ALDH(-) HLE cells exhibited a higher invasion rate than their positive counterparts. HLE and HLF cells acquired EMT in double negative subpopulations. Hh activity in Huh-7 CD133(-)/EpCAM(-) cells was higher than in their positive counterparts, and the inhibition of Hh activity by cyclopamine resulted in reduced cell proliferation.

Conclusions: Well-differentiated CD133(+)/ALDH(high) or CD133(+)/EpCAM(+) cells appear to be a CSC/initiating subpopulation; whereas, in poorly-differentiated hepatoma cells, EMT and enhanced hedgehog signaling activity may be responsible for their chemoresistance and invasion. These findings underscore the significance of EMT and enhanced Hh signaling in liver cancer stem or initiating cells.

Citing Articles

Notch and Hedgehog Signaling Unveiled: Crosstalk, Roles, and Breakthroughs in Cancer Stem Cell Research.

Iluta S, Nistor M, Buruiana S, Dima D Life (Basel). 2025; 15(2).

PMID: 40003637 PMC: 11856057. DOI: 10.3390/life15020228.


analysis of lncRNA-miRNA-mRNA signatures related to Sorafenib effectiveness in liver cancer cells.

Cruz-Ojeda P, Parras-Martinez E, Rey-Perez R, Muntane J World J Gastroenterol. 2025; 31(3):95207.

PMID: 39839902 PMC: 11684161. DOI: 10.3748/wjg.v31.i3.95207.


Antagonism of the ATP-gated P2X7 receptor inhibits the proliferation of hepatocellular carcinoma cells.

Tantai X, Yang X, Liu X, Yang X Purinergic Signal. 2024; .

PMID: 39549156 DOI: 10.1007/s11302-024-10064-5.


Targeted therapy of cancer stem cells: inhibition of mTOR in pre-clinical and clinical research.

Son B, Lee W, Kim H, Shin H, Park H Cell Death Dis. 2024; 15(9):696.

PMID: 39349424 PMC: 11442590. DOI: 10.1038/s41419-024-07077-8.


Competing endogenous RNAs regulatory crosstalk networks: The messages from the RNA world to signaling pathways directing cancer stem cell development.

Aria H, Azizi M, Nazem S, Mansoori B, Darbeheshti F, Niazmand A Heliyon. 2024; 10(15):e35208.

PMID: 39170516 PMC: 11337742. DOI: 10.1016/j.heliyon.2024.e35208.


References
1.
Vincent T, Neve E, Johnson J, Kukalev A, Rojo F, Albanell J . A SNAIL1-SMAD3/4 transcriptional repressor complex promotes TGF-beta mediated epithelial-mesenchymal transition. Nat Cell Biol. 2009; 11(8):943-50. PMC: 3769970. DOI: 10.1038/ncb1905. View

2.
Lingala S, Cui Y, Chen X, Ruebner B, Qian X, Zern M . Immunohistochemical staining of cancer stem cell markers in hepatocellular carcinoma. Exp Mol Pathol. 2010; 89(1):27-35. PMC: 2900434. DOI: 10.1016/j.yexmp.2010.05.005. View

3.
Romer J, Kimura H, Magdaleno S, Sasai K, Fuller C, Baines H . Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1(+/-)p53(-/-) mice. Cancer Cell. 2004; 6(3):229-40. DOI: 10.1016/j.ccr.2004.08.019. View

4.
Perez-Saborido B, de los Galanes S, Meneu-Diaz J, Jimenez Romero C, Moreno Elola-Olaso A, Fundora Suarez Y . Tumor recurrence after liver transplantation for hepatocellular carcinoma: recurrence pathway and prognostic factors. Transplant Proc. 2007; 39(7):2304-7. DOI: 10.1016/j.transproceed.2007.06.059. View

5.
Yamashita T, Ji J, Budhu A, Forgues M, Yang W, Wang H . EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology. 2009; 136(3):1012-24. PMC: 2828822. DOI: 10.1053/j.gastro.2008.12.004. View